Showing posts with label Hematology. Show all posts
Showing posts with label Hematology. Show all posts

07 March 2012

Prothrombin Complex Concentrate



Coagulation  Factor Disorders
Dr. N. Singh, Dr. O. Ingaramo, Dr. S. Manuel
Grandroundsepistaxis.ppt

Inhibitors of  Coagulation
Presented by  Dr. Morayma Reyes
Coagulation.ppt

Hemophilias
Cara Calvo, MS, MT(ASCP), SH(ASCP)
Hemophilias.ppt

Bleeding  Disorders
Morey A. Blinder,  M.D.
Bleeding  Disorders.ppt

Hemophilia  A
Hemophilia  A.ppt

Acquired Bleeding  Disorders
Steven Pipe,  MD
Pipe.AcquiredBleeding.ppt

Clinical  Trials in Surgery
Mazen  S. Zenati, MD, MPH, Ph.D.
Clinical  Trials in Surgery.ppt

Excessive  Warfarin Anticoagulation and Reversal Strategies  in Asymptomatic Patients
Heather  M. Powers, MD
Excesswarfarin.ppt

Introduction  to Bleeding Disorders:
Liver Disease, Renal Disease and Vitamin K Deficiency
Cara Calvo, MS, MT(ASCP), SH(ASCP)
BleedDisorders.ppt

Hot  Topics In Anticoagulation
Deborah Zeitlin,  Pharm.D.
Topics In Anticoagulation.ppt

Rituxan for treatment of idiopathic factor VIII inhibitors
Timothy S. Fenske, M.D.
VIII inhibitors .ppt

Blood  Administration
Bloodlab.ppt
Prothrombin-complex-concentrate PDFs

Read more...

04 March 2012

Neutropenia Ppt




Neutropenia is a syndrome of dangerously or abnormally low count of neutrophils in the blood.

Evaluation  and Management of Fever in the Neutropenic  Patient
Kevin  P. High, M.D., M.Sc
Neutropenic  Patient .ppt

Severe Congenital  Neutropenia
Severe Congenital  Neutropenia.ppt

Diagnosis  and Empiric Treatment  of Neutropenic Fever  in the Emergency Room
Diagnosis  and Empiric Treatment.ppt

Cyclic Neutropenia
Neutropenia.ppt

Febrile Neutropenia
FEBRILE_NEUTROPENIA_final_7-29.ppt

Fever  and Neutropenia
Fever_with_neutropenia_v2.ppt

Aplastic  Anemia
Rakesh  Biswas 
Aplastic  Anemia.ppt

Severe Congenital  Neutropenia (Kostmann’s Syndrome)
Severe Congenital  Neutropenia.ppt

White  Blood Cell Disorders
MyeloidCellDisorders.ppt

Read more...

22 December 2011

Polycythemia vera ppts and latest articles




Myeloproliferative Disorders
Alice Ma, M.D.
http://www.med.unc.edu/medicine/web/6.11.07%20Myeloproloferative%20Ma.ppt

Polycythemia Vera
http://www.med.unc.edu/medicine/web/2.28.08%20PVC%20Gibbs.ppt

Diagnostic  Approach to Myeloproliferative Neoplasms
Stephen  Oh, M.D, Ph.D.
http://hematology.wustl.edu/conferences/presentations/Oh20110819.ppt

Chronic  Myeloid Leukemia and  other Myeloproliferative  Neoplasms (MPNs)
by Dale Bixby,  M.D., Ph.D
http://open.umich.edu/sites/default/files/2580/011309.DBixby.MyeloproliferativeDisorders.ppt

Hypercoagulable  States: Polycythemia Vera
by Chris  Caulfield
https://medicine.med.unc.edu/education/internal-medicine-residency-program/files/ppt/10.20.09%20Caulfield%20Polycythemia%20vera.ppt

Neoplastic  Disorders of The Bone  Marrow
http://instructional1.calstatela.edu/nmcquee/Micro410/Lecture%2013%20-%20Neoplastic%20disorders%20of%20the%20bone%20marrow.ppt

Polycythemia Vera
http://www.medicine.wisc.edu/~williams/polycythemia.ppt

Latest 20 articles

Read more...

05 April 2011

Anemia Presentations



Aplastic anemia
http://instructional1.calstatela.edu/nmcquee/Micro410/Lecture%206%20-%20Aplastic%20and%20Hypoplastic%20Anemias.ppt

Aplastic anemia Morphologic, Etiologic Possible causes, Investigations and treatment
http://www.pitt.edu/~super4/35011-36001/35321.ppt

Hemolytic Anemias - Anemia of increased destruction
http://www.cumc.columbia.edu/dept/ps/2004/Academic/second_year/hematology/Hemolytic%20Anemia.ppt

Hepatitis –Associated Aplastic Anemia
http://medicine.georgetown.edu/residency/scholarly/researchday2009/Rizo.ppt

Anemia Presented by Manny Ramos RN, MSN
http://faculty.valenciacc.edu/jclark/Manny/studentHemaDO.ppt

Aplastic anemia
http://faculty.ksu.edu.sa/11423/Documents/aplastic%20anemia.ppt

Definition, Measurements, Symptoms of Anemia by Michele Ritter, M.D.
http://www9.georgetown.edu/faculty/wheltosa/Shelly_Anemia.ppt

Fanconi’s Anemia: Research in Another Form of Community by Sadie P. Hutson, PhD, RN, WHNP
http://www.etsu.edu/health/downloads/Hutson_12_06_06.ppt

Azathioprine and acquired aplastic anemia By Morey Blinder
http://hematology.wustl.edu/conferences/presentations/Blinder20050429.ppt

Neonatal Anemia By Kirsten E. Crowley, MD
http://www.ohsu.edu/xd/health/services/doernbecher/research-education/education/med-education/upload/Neonatal-Anemia.ppt

Hematology Red Blood Cell Disorders by Laura C. Michaelis, M.D
http://www.stritch.luc.edu/depts/medicine/residency/May_Board_Review/ACP%20RBCs%20LCM%202009.ppt

Hemolytic Anemia, Normocytic anemia, Fanconi anemia
http://www.hawaii.edu/medtech/MEDT451/Hemolytic_files/Hemolytic.ppt

Anemia Overview by Anu Thummala, M.D.
http://www.medicine.nevada.edu/residency/lasvegas/internalmed/documents/dr.thummalalecture_000.ppt

Hematopoietic System- Bone Marrow Hematopoiesis by Linda F. Cunningham, MD
http://www.hsc.unt.edu/tcom2006/histoBoneMarrow.ppt

Medical Nutrition Therapy for Anemia
http://www3.uakron.edu/chima/Nutrition%20in%20Med%20Sci%20I/anemia%20mnt.ppt

Read more...

11 July 2010

Hematology Presentations



Monoclonal Gammopathies

Hypomethylation:Turning on silenced genes and silencing the critics?

Aurora Kinases As  Anti-Cancer Targets

Bleeding Disorders

Renal Disorders in Multiple Myeloma Hematology Grand Rounds

Management of AMI in old patient

Adjuvant Therapy for NSCLC

Hairy Cell Leukemia

Follicular Lymphomas  A Post ASH Update Grand Rounds 10 Dec 2004

Gastrointestinal Stromal Tumors

Esophageal Cancer and Combined modality Treatment

Sickle Cell Hepatopathy: The role of transplantation


Read more...

03 April 2010

Hemolytic Disease of the Newborn



Hemolytic Disease of the Newborn, Current Methods of Diagnosis and Treatment
By:Terry Kotrla, MS, MT(ASCP)BB

Objectives
* List the classifications of Hemolytic Disease of the Newborn and the most antibody specificities involved.
* State the testing to perform on the mother to monitor the severity of HDN.
* List the laboratory tests and values which indicate that an infant is affected by HDN both in the fetus and newborn.
* State the treatment options for intrauterine treatment of HDN.
* State the treatment options for HDN in the moderately and severely affected newborn.
* State the requirements of blood to be used for transfusion of the fetus and newborn.

Cause of Hemolytic Disease
* Maternal IgG antibodies directed against an antigen of paternal origin present on the fetal red blood cells.
* IgG antibodies cross the placenta to coat fetal antigens, cause decreased red blood cell survival which can result in anemia.
* Produced in response to previous pregnancy with antigen positive fetus OR exposure to red blood cells, ie transfusion.

Three Classifications of HDN
* ABO
* “Other” – unexpected immune antibodies other than anti-D – Jk, K, Fy, S, etc.
* Rh – anti-D alone or may be accompanied by other Rh antibodies – anti-C, -c, -E or –e.

ABO Hemolytic Disease
* Mother group O, baby A or B
* Group O individuals have anti-A, -B and –A,B in their plasma, fetal RBCs attacked by 2 antibodies
* Occurs in only 3%, is severe in only 1%, and <1:1,000 require exchange transfusion. * The disease is more common and more severe in African-American infants. “Other” Hemolytic Disease * Uncommon, occurs in ~0.8% of pregnant women. * Immune alloantibodies usually due to anti-E, -c, -Kell, -Kidd or -Duffy. * Anti-K o disease ranges from mild to severe o over half of the cases are caused by multiple blood transfusions o is the second most common form of severe HDN * Anti-M very rare Rh Hemolytic Disease * Anti-D is the commonest form of severe HDN. The disease varies from mild to severe. * Anti-E is a mild disease * Anti-c can range from a mild to severe disease - is the third most common form of severe HDN * Anti-e - rare * Anti-C - rare * antibody combinations (ie anti-c and anti-E antibodies occurring together) - can be severe HDN * Maternal antibodies destroy fetal red blood cells o Results in anemia. o Anemia limits the ability of the blood to carry oxygen to the baby's organs and tissues. * Baby's responds to the hemolysis by trying to make more red blood cells very quickly in the bone marrow and the liver and spleen. o Organs enlarge - hepatosplenomegaly. o New red blood cells released prematurely from bone marrow and are unable to do the work of mature red blood cells. * As the red blood cells break down, bilirubin is formed. o Babies unable to get rid of the bilirubin. o Builds up in the blood (hyperbilirubinemia ) and other tissues and fluids of the baby's body resulting in jaundice. o The placenta helps get rid of some of the bilirubin, but not all. Complications During Pregnancy * Severe anemia with enlargement of the liver and spleen When these organs and the bone marrow cannot compensate for the fast destruction of red blood cells, severe anemia results and other organs are affected. * Hydrops Fetalis This occurs as the baby's organs are unable to handle the anemia. The heart begins to fail and large amounts of fluid build up in the baby's tissues and organs. A fetus with hydrops is at great risk of being stillborn. Hydrops Fetalis Clinical Presentation * Varies from mild jaundice and anemia to hydrops fetalis (with ascites, pleural and pericardial effusions) * Chief risk to the fetus is anemia. * Extramedullary hematopoiesis due to anemia results in hepatosplenomegaly. * Risks during labor and delivery include: o asphyxia and splenic rupture. * Postnatal problems include: o Asphyxia o Pulmonary hypertension o Pallor (due to anemia) o Edema (hydrops, due to low serum albumin) o Respiratory distress o Coagulopathies ( platelets & clotting factors) o Jaundice o Kernicterus (from hyperbilirubinemia) o Hypoglycemia (due to hyperinsulinemnia from islet cell hyperplasia) Kernicterus * Kernicterus (bilirubin encephalopathy) results from high levels of indirect bilirubin (>20 mg/dL in a term infant with HDN).
* Kernicterus occurs at lower levels of bilirubin in the presence of acidosis, hypoalbuminemia, prematurity and certain drugs (e.g., sulfonamides).
* Affected structures have a bright yellow color.
* Unbound unconjugated bilirubin crosses the blood-brain barrier and, because it is lipid soluble, it penetrates neuronal and glial membranes.
* Bilirubin is thought to be toxic to nerve cells
* The mechanism of neurotoxicity and the reason for the topography of the lesions are not known.
* Patients surviving kernicterus have severe permanent neurologic symptoms (choreoathetosis, spasticity, muscular rigidity, ataxia, deafness, mental retardation).

Laboratory Findings
* Vary with severity of HDN and include:
* Anemia
* Hyperbilirubinemia
* Reticulocytosis (6 to 40%)
* nucleated RBC count (>10/100 WBCs)
* Thrombocytopenia
* Leukopenia
* Positive Direct Antiglobulin Test
* Hypoalbuminemia
* Rh negative blood type or ABO incompatibility
* Smear: polychromasia, anisocytosis, no spherocytes

Blood Smear
* Polychromasia
* Anisocytosis
* Increase NRBCs
* no spherocytes

Blood Bank Testing
Bilirubin Nomogram
* Total Serum Bilirubin (TSB) monitored to determine risk of kernicterus.
* Measure bilirubin in cord blood and at least every 4 hours for the first 12 to 24 hours. Plot bilirubin concentrations over time.

Transcutaneous Monitoring
* Transcutaneous bilirubinometry can be adopted as the first-line screening tool for jaundice in well, full-term babies.
* This leads to about 50% decrease in blood testing.
* http://tinyurl.com/36jazx

Intrauterine Transfusion (IUT)
* Given to the fetus to prevent hydrops fetalis and fetal death.
* Can be done as early as 17 weeks, although preferable to wait until 20 weeks
* Severely affected fetus, transfusions done every 1 to 4 weeks until the fetus is mature enough to be delivered safely. Amniocentesis may be done to determine the maturity of the fetus's lungs before delivery is scheduled.
* After multiple IUTs, most of the baby’s blood will be D negative donor blood, therefore, the Direct Antiglobulin test will be negative, but the Indirect Antiglobulin Test will be positive.
* After IUTs, the cord bilirubin is not an accurate indicator of rate of hemolysis or of the likelihood of the need for post-natal exchange transfusion.

Intrauterine Transfusion
* An intrauterine fetal blood transfusion is done in the hospital. The mother may have to stay overnight after the procedure.
* The mother is sedated, and an ultrasound image is obtained to determine the position of the fetus and placenta.
* After the mother's abdomen is cleaned with an antiseptic solution, she is given a local anesthetic injection to numb the abdominal area where the transfusion needle will be inserted.
* Medication may be given to the fetus to temporarily stop fetal movement.
* Ultrasound is used to guide the needle through the mother's abdomen into the fetus's abdomen or an umbilical cord vein.
* A compatible blood type (usually type O, Rh-negative) is delivered into the fetus's abdominal cavity or into an umbilical cord blood vessel.
* The mother is usually given antibiotics to prevent infection. She may also be given tocolytic medication to prevent labor from beginning, though this is unusual.
* Increasingly common and relatively safe procedure since the development of high resolution ultrasound particularly with colour Doppler capability.
* MCA Doppler velocity as a reliable non-invasive screening tool to detect fetal anemia.
o The vessel can be easily visualized with color flow Doppler as early as 18 weeks’ gestation.
o In cases of fetal anemia, an increase in the fetal cardiac output and a decrease in blood viscosity contribute to an increased blood flow velocity
* The risk of these procedures is now largely dependent on the prior condition of the fetus and the gestational age at which transfusion is commenced.
* Titer greater than 32 for anti-D and 8 for anti-K OR four fold increase in titer indicates need for analysis of amniotic fluid.
* Amniocentesis
o Perform at 28 wks if HDN in previous child
o Perform at 22 wks if previous child severely affected
o Perform if maternal antibody increases before 34th wk.
* High values of bilirubin in amniotic fluid analyses by the Liley method or a hemoglobin concentration of cord blood below 10.0 g/mL.
* Type fetus -recent development in fetal RhD typing involves the isolation of free fetal DNA in maternal serum. In the United Kingdom, this technique has virtually replaced amniocentesis for fetal RhD determination in the case of a heterozygous paternal phenotype
* Maternal plasma exchange may be instituted if the fetus is too young for intrauterine transfusion.

Liley Graph
Selection of Blood
* CPD, as fresh as possible, preferably <5 days old. * A hematocrit of 80% or greater is desirable to minimize the chance of volume overload in the fetus. * The volume transfused ranges from 75-175 mL depending on the fetal size and age. * CMV negative * Hemoglobin S negative * IRRADIATED * O negative, lack all antigens to which mom has antibodies and Coomb’s compatible. Treatment of Mild HDN * Phototherapy is the treatment of choice. * Phototherapy process slowly decomposes/converts bilirubin into a nontoxic isomer, photobilirubin, which is transported in the plasma to the liver. * HDN is judged to be clinically significant (phototherapy treatment) if the peak bilirubin level reaches 12 mg/dL or more. Bilirubin Degradation by Phototherapy Phototherapy * The therapy uses a blue light (420-470 nm) that converts bilirubin so that it can be excreted in the urine and feces. * Soft eye shields are placed on the baby to protect their eyes from damage that may lead to retinopathy due to the bili lights. Phototherapy * Lightweight, fiberoptic pad delivers up to 45 microwatts of therapeutic light for the treatment of jaundice while allowing the infant to be swaddled, held and cared for by parents and hospital staff. * Compact unit is ideal for hospital and homecare. Exchange Transfusion * Full-term infants rarely require an exchange transfusion if intense phototherapy is initiated in a timely manner. * It should be considered if the total serum bilirubin level is approaching 20 mg/dL and continues to rise despite intense in-hospital phototherapy. * The procedure carries a mortality rate of approximately 1% and there may be substantial morbidity Goals of Exchange Transfusion * Remove sensitized cells. * Reduce level of maternal antibody. * Removes about 60 percent of bilirubin from the plasma, resulting in a clearance of about 30 percent to 40 percent of the total bilirubin. * Correct anemia by providing blood that will have normal survival. * Replacement with donor plasma restores albumin and any needed coagulation factors. * Rebound – usually a 2 volume exchange is needed as bilirubin in tissues will return to blood stream. Testing Baby * Antibody elution testing from cord red blood cells. * ABO/D typing o If baby received intrauterine transfusions will type as O negative o If baby’s Direct Antiglobulin Test is strongly positive due to anti-D may get FALSE NEGATIVE immediate spin reaction with reagent anti-D (blocking phenomenon), weak D (Du) test will be STRONGLY positive * Antibody screen * Coomb’s crossmatch antigen negative donor. Testing Mom * Type and screen on mom. * Identification of unexpected antibodies. * More than 40 antigens have been identified as causing HDN. * Select blood that lacks antigens to which mom has antibodies. * Perform coomb’s crossmatch with Mom and baby’s blood. Selection of Donor Blood * CPD, as fresh as possible, preferably <5 days old. * CMV negative * Hemoglobin S negative * Irradiated if possible Preparation of Donor Unit * Physician will specify a hematocrit. * Reconstitute donor unit with plasma. * Most facilities prefer to use group O red cells and AB plasma. * Reference for procedure at end of this presentation. Summary * Three types of HDN vary in severity. * Laboratory testing key to diagnosing and monitoring- great care to be taken when interpreting ABO/D typing on affected infants. * Therapy dependent on severity: phototherapy alone or with transfusion. References Hemolytic Disease of the Newborn, Current Methods of Diagnosis and Treatment.ppt

Read more...

17 January 2010

Lupus Anticoagulant



Lupus Anticoagulant
By:Jennifer Kirkland (Lambe)

Antiphospholipid
Antibody Syndrome
* Antibodies to phospholipids or plasma proteins bound to phospholipids
o Lupus anticoagulant antibodies
o Anticardiolipin antibodies
o Anti-ß2- glycoprotein I antibodies
* Other antibodies: prothrombin, annexin V, phosphatidylserine, phosphatidylinositol
o These antibodies are not standardized for clinical use and their clinical utility is not well characterized

Lupus anticoagulant
* Lupus anticoagulant
o Describes a group of antibodies which react with cardiolipins, other phospholipids, ß2-glycoprotein I, or proteins other than ß2-glycoprotein I
-AND-
o possess “lupus anticoagulant” activity

What is lupus anticoagulant activity?

* Ability to interfere with coagulation testing (in particular, the tests which are phospholipid dependent) leading to prolonged values
* Despite the “anticoagulant effect” in vitro, these antibodies actually cause coagulation in vivo, in the form of arterial and venous thromboses

Lupus anticoagulant:
Actually a Misnomer
* Associated with clotting, not anticoagulation
* More than one antibody is associated with lupus anticoagulant activity
* Only about 50% of individuals with a lupus anticoagulant meet the American College of Rheumatology criteria for the classification of lupus (SLE)

Definitions
* Cardiolipin= mitochondrial phospholipid
o Causes a biologic false positive test for syphilis
* ß2-glycoprotein I -(not a phospholipid but a plasma phospholipid binding protein)
o In early 1990s, discovery that some anticardiolipin antibodies require the presence of ß2-glycoprotein I in order to bind to cardiolipin
o Patients with SLE or the antiphospholipid syndrome require ß2-glycoprotein I in order to bind to cardiolipin
o Most ß2-glycoprotein I-dependent anticardiolipin antibodies recognize ß2-glycoprotein I equally well whether bound to cardiolipin or bound to other anionic phospholipids

Additional info on LAs
* Anticardiolipin antibodies and Anti-ß2- glycoprotein I antibodies may not possess lupus anticoagulant properties
* Specificity of anticardiolipin antibodies for antiphospholipid syndrome increases with titer and is higher for the IgG than for the IgM isotope
* There is no definitive association between specific clinical manifestations and particular subgroups of antiphospholipid antibodies


Effects of antiphospholipid antibodies on coagulation
* Actually has opposing effects on coagulation
Procoagulant Effects
* Inhibits activated protein C pathway
* Up-regulates TF pathway
* Inhibits antithrombin III activity
* Disrupts annexin V shield on membranes
* Inhibits anticoagulant activity of ß2-glycoprotein I
* Inhibits fibrinolysis
* Activates endothelial cells
* Activates and degranulates neutrophils
* Enhances expression of adhesion moleculres by endothelial cells and adherence of neutrophils and leukocytes to endothelial cells
* Potentiates platelet activation
* Enhances platelet aggregation
* Enhanced binding of ß2-glycoprotein I to membranes
* Enhanced binding of prothrombin to membranes
Anticoagulant Effect
* Inhibits activation of factor IX
* Inhibits activation of factor X
* Inhibits activation of prothrombin to thrombin
o “Microenvironment of cell membranes in vivo may promote greater inhibition of anticoagulant pathways and therefore thrombosis.”
o Ultimately, we don’t really know the mechanism by which thrombosis is promoted over anticoagulation

Criteria for detection of lupus anticoagulant antibodies
* Lupus anticoagulant
1. Must prolong coagulation in at least one phospholipid-dependent coagulation assay with the use of platelet poor plasma
+ Extrinsic (dPT)
+ Intrinsic (aPTT, dilute aPTT, KCT, colloidal silica clotting time)
+ Final common pathway (dRVVT, Taipan venom time, Textarin and Ecarin time)

2. Failure to correct the prolonged coagulation time by mixing the patient’s plasma with normal plasma (1:1)
3. Correction of the prolonged coagulation time after addition of excess phospholipid or platelets that have been frozen and then thawed (they release phospholipids)
4. Rule out other coagulopathies with the use of specific factor assays if the confirmatory test is negative or if a specific factor inhibitor is suspected

To rule out a lupus anticoagulant antibody
* Two or more assays that are sensitive to these antibodies must be negative (one should be based on low phospholipid concentration and they should evaluate distinct portions of the coagulation cascade)

Diagnosis of antiphospholipid antibody syndrome
* Clinical Criteria
o Vascular thrombosis (Venous or arterial: blood vessels, brain, kidneys, lung GI tract, placenta etc)
o 1 or more deaths of normal fetuses at or after 10th week of gestation,or 1 or more premature births at or before the 34th week of gestation; or 3 or more unexplained consecutive spontaneous abortions before the 10th week of gestation

* Laboratory criteria
o Anticardiolipin antibodies
+ Anticardiolipin IgG or IgM antibodies present at moderate or high levels in the blood on two or more occasions at least 6 weeks apart
o Lupus anticoagulant antibodies
+ LA detected in the blood on 2 or more occasions at least 6 weeks apart (?12 weeks)

Antiphospholipid syndrome
* Primary
o No other evidence of another autoimmune disease
* Secondary
o Associated with autoimmune or other diseases, most commonly SLE
* Sneddon’s syndrome: clinical triad of stroke, livedo reticularis, and hypertension may represent undiagnosed antiphospholipid syndrome.


Epidemiology
* Antiphospholipid antibodies are found among young, apparently healthy control subjects at a prevalence of 1 to 5% for both anticardiolipin antibodies and lupus anticoagulant antibodies
o Meta-analysis
+ LA= 11.1 Odds ratio for venous thrombosis compared with 3.21 with anticardiolipin Ab
o Multivariant analysis
+ Odds ratio for venous and arterial thromboembolism is 4.4 with LA and 1.2 with anticardiolipin
* Prevalence increases with age

Prevalence of LAs in patients with SLE
* Anticardiolipin antibodies= 12-30%
* Lupus anticoagulant antibodies= 15-34%
* B2glycoprotein I antibodies=20%
o Antiphospholipid syndrome may develop in 50 to 70% of patients with both SLE and antiphospholipid antibodies after 20 years of follow-up
o Up to 30% of patients with SLE and anticardiolipin antibodies lacked any clinical evidence of the antiphospholipid syndrome over an average follow-up of seven years

Prospective study
* In a recent prospective study involving individuals with antiphospholipid antibodies, the incidence of thrombosis per year was:
o 1% in individuals with no history of thrombosis
o 4% in patients with systemic lupus erythematosus
o 5.5% in patients with a history of thrombosis
o 6% in individuals with high titer IgG anticardiolipin antibody (>40 units).

Functional Assays of Lupus Anticoagulants
* aPTT
o Some manufacturers offer aPTT reagent which contains a low amount of phospholipid, therefore it is more sensitive for lupus anticoagulant
o Conditions causing acute phase reactants associated with increased fibrinogen and factor VIII, may shorten the aPTT and mask a weak LA
* Prothrombin Time:
o patients with LA will have a normal PT unless they are receiving oral anticoagulants or they develop an inhibitor to prothrombin (PT reagents contain more phospholipids than PTT reagents)

* DRVVT (screening)
o Activates factor X which in the presence of PL, calcium, and factor V activates prothrombin, leading to the formation of a fibrin clot
o Dilution of the venom yields a clotting time in which concentration of the PL reagent is the rate limiting step (there is low amount of phospholipids)
o Inhibition by LA leads to prolongation
o After positive screen, perform the mixing study- if does not correct then:
* DRVVT (confirm)
o Adds a higher amount of phospholipids to neutralize the lupus anticoagulant
o Ratio is derived from the screen clotting time divided by the confirmatory clotting time
o If ratio exceeds the established cutoff, then lupus anticoagulant is in the specimen

Tissue thromboplastin inhibition test (TTI)
o Modified PT assay
o Thromboplastin, which is rich in phospholipid, can be diluted so that its concentration becomes the rate limiting step
o Inhibition of prothrombinase by a LA will cause prolongation of the PT assay
o Due to the various PL and its concentration in the reagent, the test varies in its sensitivity and specificity

STACLOT LA: Hexagonal II Phase Phospholipid Assay
* Two part aPTT screening assay for LA
* Patient’s plasma is mixed with buffer (screening test) or hexagonal phase phosphatidyl ethanolamine (confirmatory test) to neutralize any lupus anticoagulant present
* Mixtures are incubated with normal plasma to correct any coagulation factor deficiency
* Measure aPTT in both mixtures
* If specimen contains LA, the aPTT of the confirmatory test will be significantly shorter than that of the screening test

Staclot-LA
* Phospholipid antibody positive= difference in the clotting times between the two tubes is greater than + 8.0 seconds.
* The aPTT reagent in this assay contains a heparin inhibitor which makes the test system insensitive to heparin levels up to 2.0 U/mL.
* False positive results may occur in patients with high titer Factor VIII inhibitors

Summary
* Lupus anticoagulant causes thrombosis
* Lupus anticoagulant is a group of antibodies that bind to phospholipids or phospholipid binding proteins
* Due to the heterogeneity of the phospholipid antibody, there is no single test that is confirmatory for all phospholipid dependent antibodies.

References

* Kaolin clotting time
o Sensitive for LA when no additional PL is used
o LA is identified when the KCT fails to correct after the addition of even large amounts of plasma
o Problems with the KCT, owing to the particular nature of kaolin, is that it is unsuitable for some photo-optical devices, which makes full automation difficult
* Taipan (Oxysuranus scutellatus) venom activates prothrombin in the presence of PL and Ca2+
* Textarin (Pseudonaja textiles) acts similarly but requires the presence of factor V
* Specificity of both of the above tests can be improved by mixing tests and/or confirmation with the use of ecarin, an enzyme purified from the venom of Echis carinatus, in conjunction with the Textarin test

Lupus Anticoagulant.ppt

Read more...

Antiphospholipid Antibody Syndrome in Children



Antiphospholipid Antibody Syndrome in Children
By:Jill Glassberg Azok
Grand Rounds
January 23, 2009

Case: OL

* HPI: 2 yo female with Trisomy 21, Tetralogy of Fallot
o 7/9/08: surgical repair of TOF
o 7/31: re-exploration of surgical wound due to wound dehiscense, cultures +pseudomonas
o 7/31: developed rash on buttocks, trunk, described as “red, circular spots”; initially thought to be Candida
+ Over the next 2 wks, developed petechiael rash of her trunk, feet
+ Rash became diffuse erythroderma with resolution of petechiae
o 8/15: returned to OR for exploration of sternal wound due to fever, respiratory distress, and rash; no evidence of infection
o 8/22: returned to OR sternal non-union
+ cultures +corynebacterium and enterococcus facaelis


* PMHx
o DOL 3: TE fistula repair
o DOL 9: modified BT shunt
o Post-op course complicated by thrombus in iliac and aorta, requiring thrombectomy
o Hypothyroidism
o Trisomy 21
o Tetralogy of Fallot with pulmonary atresia
o Chronic lung disease requiring tracheostomy and ventilator
Labs
* Lupus anticoagulant: positive
* Russel viper venom test: negative
* Cardiolipin antibody: positive
o IgM: indeterminate, IgA/IgG: negative
* Beta-2-Glycoprotein-I
o IgM: negative, IgA/IgG: positive
* Phosphatidylserine antibodies
o IgA, IgG, IgM-negative
* Skin biopsy
o Marked hemorrhage in the superficial dermis; prominent fibrin thrombi with white blood cells occluding the vessels of the superficial vascular plexus.
o Given the occlusion and lack of inflammation around the vessels, we favor the extravasation of red blood cells is secondary to the occlusion and not secondary to a vasculitis.

Hospital Course
* Diagnosed with Catastrophic Antiphospholipid Antibody Syndrome: Treated with IVIG 5mg/kg
* 8/26: Decreased perfusion, increased lactate, decreased urine output, firm abdomen, guaic positive stools
o KUB: pneumatosis with possible portal venous gas formation
o Taken To OR for concern for necrotizing enterocolitis;
o Exploratory laparotomy and ileocolic resection
o Small intestine had diffuse areas of necrotizing enterocolitis with poor perfusion
o Right colon and the transverse colon were distended with evidence of full-thickness injury and vessel thrombosis
o Returned to CICU on inotropic support, broad spectrum antibiotics, both chest and abdomen were open
* 8/28 worsened clinically: Back to OR
o Small bowel was necrotic with multiple areas of full-thickness injury.
o The remaining portion of the colon down to the level of the rectus was also necrotic.
o Thrombi in the distal vessels and at the end branches of the mesenteric vessels
o She had a complete colectomy with resection of most of her small bowel
* 8/29: family decided to withdraw care: patient expired
* Autopsy: Cause of death listed as catastrophic antiphospholipid antibody syndrome

Antiphospholipid Antibody Syndrome
* Multisystem autoimmune disease
* Most common cause of acquired thrombophilia
* History
o 1906: antiphospholipid antibody discovered in patients with syphilis, complement-fixing antibody that reacted with extracts from bovine hearts
o 1952: Conley and Hartmann described circulating anticoagulant in patients with Lupus
o 1963: Bowie associated the anticoagulant with thromboembolic events
* Epidemiology
o Most common in young to middle-age adults
o Can occur in children and elderly
o More common in females

* Diagnosis
o At least one antiphospholipid antibody
o At least one clinical manifestation
* May be primary or secondary


CLINICAL CRITERIA
1. Vascular thrombosis: One or more clinical episodes of arterial, venous, or small vessel thrombosis, in any tissue or organ.
2. Pregnancy morbidity

A. One or more unexplained deaths of a morphologically normal fetus at or beyond the tenth week of gestation, with normal fetal morphology documented by ultrasound or by direct examination of the fetus, or

B. One or more premature births of a morphologically normal neonate at or before the thirty-fourth week of gestation because of severe preeclampsia or eclampsia, or severe placental insufficiency, or

C. Three or more unexplained consecutive spontaneous abortions before the tenth week of gestation, with maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes excluded


LABORATORY CRITERIA

1. aCL of IgG and/or IgM isotype in blood, present in medium or high titer, on two or more occasions at least 6 weeks apart, measured by a standardized ELISA for β2-GPI–dependent aCL.

2. Lupus anticoagulant present in plasma, on two or more occasions at least 6 weeks apart, detected according to the guidelines of the International Society on Thrombosis and Hemostasis (Scientific Subcommittee on Lupus Anticoagulant/Phospholipid-Dependent Antibodies), in the following steps:

A. Prolonged phospholipid-dependent coagulation demonstrated on a screening test (eg, activated partial thromboplastin time [aPTT], kaolin clotting time, dilute Russell's viper venom time, dilute prothrombin time, Texarin time)

B. Failure to correct the prolonged coagulation time on the screening test by mixing with normal platelet-poor plasma

C. Shortening or correction of the prolonged coagulation time on the screening test by the addition of excess phospholipid

D. Exclusion of other coagulopathies (eg, factor VIII inhibitor or heparin) as appropriate

Clinical Manifestations
* Vascular thrombosis: arterial and venous
* Skin: Levido reticularis
* Recurrent pregnancy loss
* Neurologic: TIA, stroke, migraine, chorea, seizures, optic neuritis
o Sneddon Syndrome: stroke, levido reticularis, hypertension
* Cardiac: Coronary artery disease, premature atherosclerosis, vegetations
* Renal: thrombotic microangiopathy, renal vein thrombosis, renal infarction, renal artery stenosis with hypertension, increased allograft vascular thrombosis, and reduced survival of renal allografts
* Pulmonary: PE, pulmonary hypertension
* GI: Budd-Chiari syndrome, intestinal ischemia and infarction, colonic ulceration, esophageal necrosis and perforation, hepatic infarction, acalculous cholecystitis with gallbladder necrosis, and mesenteric and portal vein thrombosis
* Hematologic: thrombocytopenia, TTP/HUS, hemolytic anemia

Antiphospholipid antibodies
* Antiphospholipid antibodies present in young, healthy controls
o Studies of healthy blood donors
+ Lupus anticoagulant in 8%
+ IgG anticardiolipin in 6.5%
+ IgM anticardiolipin in 9.4%
+ <2% of healthy blood donors with elevated anticardiolipin antibody still had elevated level 9months later
o Incidence increases with age and coexisting chronic disease
* Among patients with thrombosis, prevalence of antiphospholipid antibodies is 4 to 21%
* Increasing risk of thrombosis among those with higher antibody titers

* Lupus anticoagulant: most specific
o Functional assay, measures ability to prolong clotting time
o aPTT, Russel viper venom test, kaolin clotting time
o Meta-analysis showed the odds ratio of lupus anticoagulant for stroke: 11 compared to 1.6 for anticardiolipin
* Anticardiolipin antibodies- most sensitive
* Anti-b2 Glycoprotein I antibodies
* Other antibodies of unclear significance: prothrombin, annexin V, phosphatidylserine, phosphatidylinositol, phosphatidylcholine
* Some anti-cardiolipin antibodies require presence of the plasma phospholipid-binding protein b 2-glycoprotein I in order to bind to cardiolipin
* People with syphilis or infectious diseases, antibodies bind directly to anticardiolipin, independent of /inhibited by b 2-glycoprotein-I
* Autoimmune anticardiolipin antibodies directed against phospholipid-binding protein, not phospholipid itself

Pathogenesis Theories
* Interfere with phospholipid-binding proteins involved in the regulation of the clotting cascadeprocoagulant
* Activation of endothelial cellsincreased expression of cell-surface adhesion molecules and increased secretion of cytokines and prostaglandins
* Oxidant-mediated injury of vascular endothelium
* Platelet activation

Drug Induced aPLs
* Mediations reported
o Phenothiazines
o Phenytoin
o Hydralazine
o Procainamide
o Quinidine
o Dilantin
o Ethosuximide
o Alpha-interferon
o Amoxicillin
o Chlorothiazide
o Oral contraceptives
o Propranolol
* Usually transient
* Associated with IgM
* Rarely associated with thrombosis
* Mechanism unknown

Significance of aPLs
* No history of thrombosis and positive aPL: Risk of new thrombosis <1%
* History of thrombosis and positive aPL: Risk of new thrombosis >10% in first year if anticoagulation stopped within 6 months

A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies
Ruiz-Irastorza G Database of Abstracts of Reviews of Effects 2008

* Sixteen studies were included (n=1,740)
* Thrombosis recurrence rates among untreated patients: 19 to 29% per year
* Rates of major bleeding varied widely, ranging from 0.57 to 10% per year. Seventy-four per cent of bleeding episodes occurred in patients with an INR ≥3.0
* Eighteen deaths were reported to be directly related to recurrent thromboses and one due to bleeding. Ten patients in one study died as a result of the presenting thrombosis
* Patients with definite APS and arterial and/or recurrent thrombosis are at high risk of recurrent events. Most thrombotic events in patients on warfarin occur at an INR <3; recurrences are infrequent among those with an INR of 3.0 to 4.0. Patients with venous embolism or stroke and a single positive aPL that does not persist are at relatively low risk of recurrent thrombosis.
* Recommendations: after a first venous thrombosis, patients with APS should be treated with warfarin at an INR of 2.0 to 3.0; those with arterial or secondary thrombosis should be treated with warfarin at an INR >3.0. Patients with venous thrombosis or stroke and a single positive aPL test should be retested, and should be treated no differently from other patients unless the antibody persists.

Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry
* 121 cases of antiphospholipid antibody syndrome in children in the European registry
o Mean age of onset: 10.7 years
o Slightly more common in females, 1.2:1
o 60 (49.5%) had underlying autoimmune disease
o 72 (60%) had venous thrombosis
o 39 (32%) had arterial thrombosis
o 81% had positive anticardiolipin antibodies
o 67% had positive anti-b2-glycoprotein I antibodies
o 72% had positive Lupus anticoagulant

Unique to Pediatric Population
* Lack of prothrombotic risk factors which are present in adults, ie cigarette smoking
o Frequency of vascular thrombosis lower
* Increased incidence of infection-related antiphospholipid antibodies
o Parvovirus B19, cytomegalovirus, varicella-zoster virus, HIV, streptococcal and staphylococcal infections, gram negative bacteria, mycoplasma pneumoniae
* Higher frequency of Evan’s syndrome, Raynaud’s, migraines, and chorea
* Decision-making for long term anticoagulation

Neonatal APS
* Due to transplacental passage of maternal aCL, disappear over 6months
* In pediatric age group, neonatal period highest risk for thrombosis
o Decreased Protein C, Protein S, and antithrombin
o Elevated Factor VIII and von Willebrand factor
* Despite this, very low risk of thrombosis

Catastrophic APS
* Multiple, simultaneous vascular occlusions throughout body
o Widespread microthrombi in multiple vascular bedsMassive thromboembolism
o Clinical involvement of at least 3 organ systems over days to weeks
o Histopathologic evidence of occlusions of small and large blood vessels
o Most common organs: kidney>lung>CNS>heart>skinmultiorgan failure
o DIC in 25%
o Respiratory failure, stroke, abnormal liver enzymes, renal insufficiency/failure, adrenal insufficiency, cutaneous infarcts
* Precipitating factor in 55%: Most common is infection
* Usually primary APS
* Treatment
o Treat precipitating factor if present
o Anticoagulation
o Steroids
o IVIG
o Plasma exchange
* Mortality > 50%

Antiphospholipid Antibody Syndrome in Children .ppt

Read more...

11 September 2009

Blood



BLOOD

CIRCULATORY SYSTEM
* BLOOD
* HEART
* BLOOD VESSELS

FUNCTIONS OF BLOOD
* TRANSPORT
* PROTECTION
* REGULATION

TRANSPORT
* OXYGEN (O2)
* CARBON DIOXIDE (CO2)
* NUTRIENTS
* WASTES
* HORMONES
PROTECTION
* IMMUNE SYSTEM
o WHITE BLOOD CELLS
o ANTIBODIES
* CLOTTING SYSTEM
o PLATELETS
o FIBRINOGEN / FIBRIN

REGULATION
* BODY TEMPERATURE
* pH
* WATER BALANCE
* ELECTROLYTE BALANCE

BLOOD COMPOSITION
BLOOD IS COMPRISED OF TWO MAIN COMPONENTS:
* PLASMA
* FORMED ELEMENTS
THESE COMPONENTS CAN BE SEPARATED BY CENTRIFUGATION
THE FRACTION OF THE BLOOD VOLUME COMPRISED OF RED BLOOD CELLS IS TERMED THE HEMATOCRIT

PLASMA COMPOSITION
* WATER (~90%)
* SOLUTES (~10%)
o PROTEINS (~8%)
o OTHER COMPOUNDS (~2%)
+ NUTRIENTS
+ GASES
+ WASTES
+ HORMONES
+ ELECTROLYTES

PLASMA PROTEINS
* MOST ABUNDANT PLASMA SOLUTE
* LIVER CAN PRODUCE 4 GRAMS OF PLASMA PROTEINS PER HOUR
* THREE MAJOR CATEGORIES
o ALBUMINS
o GLOBULINS
o FIBRINOGEN
ALBUMINS
* ~60% OF PLASMA PROTEINS
* SMALL
* TRANSPORT LIPIDS, HORMONES, CALCIUM, ETC.
* BUFFER BLOOD pH
* CONTRIBUTE TO VISCOSITY & OSMOLARITY
* INFLUENCE BLOOD PRESSURE, BLOOD FLOW, AND FLUID BALANCE

GLOBULINS
* ~36% OF PLASMA PROTEINS
* THREE SUBCLASSES
o ALPHA (a)
o BETA (b)
o GAMMA (g)
* ALPHA (a)
o VARIOUS FUNCTIONS, ESPECIALLY TRANSPORT
* BETA (b)
o VARIOUS FUNCTIONS, ESPECIALLY TRANSPORT
* GAMMA (g)
o COMPONENTS OF IMMUNE SYSTEM
o PRODUCED BY PLASMA CELLS, WHICH ARE DESCENDED FROM WHITE BLOOD CELLS

FIBRINOGEN
* ~4% OF PLASMA PROTEINS
* PRECURSOR OF FIBRIN
* INVOLVED IN BLOOD CLOTTING

PLASMA: NUTRIENTS
* SUGARS
* AMINO ACIDS
* FATS
* CHOLESTEROL
* PHOSPHOLIPIDS
* VITAMINS
* MINERALS

PLASMA: GASES
* OXYGEN (O2)
o REQUIRED FOR CELLULAR RESPIRATION
* CARBON DIOXIDE (CO2)
o PRODUCT OF CELLULAR RESPIRATION
* NITROGEN (N2)
o USUALLY PHYSIOLOGICALLY UNIMPORTANT
o WHY DO YOU THINK IT IS THERE?

PLASMA: WASTES
NITROGENOUS WASTES
* PRODUCTS OF CATABOLISM
o (ESP: AMINO ACID CATABOLISM)
* MOST ABUNDANT IS UREA
* REMOVED FROM BLOOD BY KIDNEYS
* EXCRETED THROUGH URINE
* RATE OF REMOVAL BALANCES RATE OF PRODUCTION

PLASMA: ELECTROLYTES
* SODIUM (Na+)
* CALCIUM (Ca2+)
* POTASSIUM (K+)
* MAGNESIUM (Mg2+)
* CHLORIDE (Cl-)
* BICARBONATE (HCO3-)
* PHOSPHATE (HPO42-)
* SULFATE (SO42-)
* VARIOUS IONS
* SODIUM IS THE MOST PREVALENT
* INCREASE BLOOD OSMOLARITY
o AFFECT BLOOD VOLUME
o AFFECT BLOOD PRESSURE

FORMED ELEMENTS
* ERYTHROCYTES (RED BLOOD CELLS)
* LEUKOCYTES (WHITE BLOOD CELLS)
* PLATELETS (CELL FRAGMENTS)

ERYTHROCYTE FUNCTIONS
* CARRY O2 FROM LUNGS TO CELLS
* CARRY CO2 FROM CELLS TO LUNGS
* HOW DO O2 AND CO2 RELATE TO THE FUNCTIONS OF A CELL?

ERYTHROCYTE QUANTITIES
* MEN: 4.6 – 6.2 MILLION/mL IN
o HEMATOCRIT 42 – 52 (% RBCs)
* WOMEN: 4.2 – 5.4 MILLION/mL
o HEMATOCRIT 37 – 48 (% RBCs)
* GENDER DIFFERENCES BASED ON:
o ANDROGENS INCREASE NUMBER
o MENSTRUAL LOSS DECREASES NUMBER
o BODY FAT (INVERSE RELATIONSHIP)
o FASTER CLOTTING IN MEN

ERYTHROCYTE STRUCTURE
* DISC SHAPED
* BICONCAVE
* 7.5 MICROMETER (mm) DIAMETER
* 2 MICROMETERS (mm) THICK

ERYTHROCYTE STRUCTURE
PLASMA MEMBRANE
* PHOSPHOLIPID BILAYER
* GLYCOPROTEINS, GLYCOLIPIDS
o DETERMINE BLOOD TYPE
* ACTIN AND SPECTRIN ON INNER SURFACE
o RESILIENCE / DURABILITY / PLIABILITY
* HIGH SURFACE AREA:VOLUME RATIO
o RESULT OF BICONCAVE SHAPE
o INCREASES RATE OF GAS DIFFUSION INTO AND OUT OF CELLS

ERYTHROCYTE STRUCTURE
CYTOPLASM
* LACKS ORGANELLES
o ESP: LACKS MITOCHONDRIA, NUCLEUS
o WHY IS THIS IMPORTANT?
o CANNOT REPAIR
o LIMITED LIFESPAN (~120 DAYS)
o CANNOT DIVIDE
o NEW CELLS FORMED IN BONE MARROW
* HEMOGLOBIN
o RED PIGMENT
o HIGH CONCENTRATION (33%)
o 280 MILLION MOLECULES PER CELL
o CARRIES MOST OF THE O2
o CARRIES SOME OF THE CO2
o PROTEIN & NON-PROTEIN COMPONENTS

HEMOGLOBIN
PROTEIN COMPONENT
* 4 POLYPEPTIDES (HETEROTETRAMER)
o 2 a-GLOBIN PROTEINS
o 2 b-GLOBIN PROTEINS
NON-PROTEIN COMPONENT
* 4 HEME GROUPS
o PORPHYRIN RING AND IRON ION
o IRON ION WITHIN HEME BINDS TO O2

ABO BLOOD TYPES
* DETERMINED BY SURFACE ANTIGENS
o GLYCOLIPIDS AND GLCOPROTEINS
+ (SUGARS ON CELL SURFACE)
o GENETICALLY DETERMINED
o RECOGNIZED BY ANTIBODIES
o INDIVIDUALS POSSESS ANTIBODIES TO ANTIGENS THEY THEMSELVES DO NOT POSSESS
o RECOGNITION OF THESE ANTIGENS BY ANTIBODIES CAUSES CELL CLUMPING
* DETERMINED BY GENE “I”
* THREE ALLELES
o IA
o IB
o i
* IA AND IB ARE CODOMINANT
* i IS RECESSIVE TO IA AND IB
* THREE ALLELES OF “I” GENE
* INDIVIDUALS POSSESS TWO COPIES
* FOUR BLOOD TYPES
o A GENOTYPE IAIA OR IAi
o B GENOTYPE IBIB OR IBi
o AB GENOTYPE IAIB
o O GENOTYPE ii

ANTIBODIES TO A AND B ANTIGENS
* APPEAR SHORTLY AFTER BIRTH
* PRESENT FOR ENTIRE LIFE
* PRODUCED IN RESPONSE TO SIMILAR ANTIGENS ON INTESTINAL BACTERIA
* CROSS-REACT WITH A AND B ANTIGENS
* TERMED “ANTI-A” AND “ANTI-B”
* CAUSE OF TRANSFUSION REACTIONS

Rh BLOOD TYPES
* DETERMINED BY SURFACE ANTIGENS
* UNRELATED TO ABO BLOOD TYPE
* GENETICALLY DETERMINED
* ALLELES OF THREE GENES
o C, c, D, d, E, e
o DD, Dd ARE Rh+
o dd MAY BE Rh-, DEPENDING ON ALLELES OF OTHER GENES
* ANTI-D ANTIBODIES NOT NORMALLY PRESENT
o PRESENT ONLY IN Rh- EXPOSED TO Rh+
o FIRST EXPOSURE NOT PROBLEMATIC
o SECOND EXPOSURE PROBLEMATIC
o TRANSFUSION / PREGNANCY
* IMMUNE RESPONSE PREVENTABLE
o RhoGAM (Rh IMMUNE GLOBULIN)

OTHER BLOOD GROUPS
* > 100 OTHER BLOOD GROUPS
* USEFUL IN GENETIC / BIOCHEMICAL TESTING
* RARELY CAUSE TRANSFUSION REACTIONS

ERYTHROCYTE DISORDERS
ANEMIA
* ERYTHROCYTE DEFICIENCY, OR
* HEMOGLOBIN DEFICIENCY
* THREE CLASSES
o INADEQUATE SYNTHESIS
o BLEEDING
o RBC DESTRUCTION
* CONSEQUENCES
o OXYGEN DEPRIVATION (HYPOXIA)
+ SHORTNESS OF BREATH
o REDUCED BLOOD OSMOLARITY
+ WATER RETENTION IN TISSUES (EDEMA)
o REDUCED BLOOD VISCOSITY
+ HEART BEATS FASTER
+ CARDIAC FAILURE
SICKLE-CELL ANEMIA
* ~0.25% OF AFRICAN AMERICANS
* GENETICALLY DETERMINED
* ABERRANT b-GLOBIN ALLELE (HbS)
o SINGLE AMINO ACID SUBSTITUTION
o GLUTAMIC ACID (HbA)  VALINE (HbS)
* CELLS SICKLE UNDER LOW OXYGEN
* MULTIPLE DELETERIOUS EFFECTS

* WHY IS THE FREQUENCY SO HIGH?
o MALARIA PREVALENT IN AFRICA
o Plasmodium PARASITE LIVES IN RBCs
o SURVIVES POORLY IN CELLS WITH HbS
o INDIVIDUALS WITH HbS LESS LIKELY TO DIE (HETEROZYGOTES MOST FIT)
o THUS, HbS PROVIDES PROTECTION

LEUKOCYTES
* 5,000 – 10,000 CELLS/mL
* FIVE TYPES:
o NEUTROPHILS 60 – 70 % 9 – 12 mM
o LYMPHOCYTES 25 – 33% 5 – 8 mM (most)
o MONOCYTES 3 – 8 % 12 – 15 mM
o EOSINOPHILS 2 – 4% 10 – 14 mM
o BASOPHILS <0.5 – 1% 8 – 10 mM
* GRANULOCYTES
o NEUTROPHILS
o EOSINOPHILS
o BASOPHILS
* AGRANULOCYTES
o LYMPHOCYTES
o MONOCYTES
LEUKOCYTES
NEUTROPHILS
* HIGHLY MOBILE
* INCREASE IN RESPONSE TO BACTERIAL INFECTIONS
* KILLS BACTERIA
o PHAGOCYTOSIS
o CHEMICALLY (BURST LYSOSOMES)

EOSINOPHILS
* INCREASE WITH ALLERGIES
* INCREASE WITH PARASITIC INFECTIONS
* PHAGOCYTOSIS
o ANTIGEN / ANTIBODY COMPLEXES
o ALLERGENS
* HYDROLYTIC ENZYME RELEASE
o RESPONSE TO HOOKWORM, TAPEWORM, ETC.
o TOO LARGE TO PHAGOCYTIZE
BASOPHILS
* GENERALLY NOT PHAGOCYTIC
* AID OTHER LEUKOCYTES
o RELEASE HISTAMINE
+ INCREASE BLOOD FLOW TO AREA
o RELEASE HEPARIN
+ INHIBIT CLOTTING
LYMPHOCYTES
* INCREASE IN IMMUNE RESPONSE
* SEVERAL SUBCLASSES
* VARIOUS IMMUNE FUNCTIONS
o ESP: SECRETE ANTIBODIES

MONOCYTES
* DIFFERENTIATE INTO MACROPHAGES
* PHAGOCYTOSIS OF PATHOGENS
* PHAGOCYTOSIS OF DEBRIS
* PRESENT ANTIGENS TO OTHER CELLS OF IMMUNE SYSTEM
PLATELETS
* 130,000 – 400,000 / mL
* NOT CELLS
o FRAGMENTS OF MEGAKARYOCYTES
o SMALL (2 – 4 mM DIAMETER)
* POSSESS VARIOUS ORGANELLES
* PSEUDOPODS
o AMOEBOID MOVEMENT
o PHAGOCYTOSIS
PLATELET FUNCTIONS
* SECRETE CLOTTING FACTORS
* SECRETE VASOCONSTRICTORS
* FORM TEMPORARY PLATELET PLUGS
* DISSOLVE OLD BLOOD CLOTS
* PHAGOCYTOSIS OF BACTERIA
* SECRETE CHEMICALS TO ATTRACT LEUKOCYTES TO SITES OF INFLAMMATION
* SECRETE GROWTH FACTORS

CONTROL OF BLEEDING
HEMOSTASIS
* VASCULAR SPASM
* PLATELET PLUG FORMATION
* COAGULATION
VASCULAR SPASM
* CONSTRICTION OF BROKEN VESSEL
* IMMEDIATE PROTECTION AGAINST BLEEDING
* MULTIPLE TRIGGERS
TRIGGERS OF VASCULAR SPASM
* PAIN RECEPTORS  NERVES  BLOOD VESSELS CONSTRICT
* SMOOTH MUSCLE OF BLOOD VESSELS CONSTRICT
* PLATELETS RELEASE SEROTONIN (CHEMICAL VASOCONSTRICTOR)
PLATELET PLUG FORMATION
* BLOOD VESSEL BROKEN
* COLLAGEN FIBERS EXPOSED
* PLATELETS BIND TO COLLAGE FIBERS
o FORM PSEUDOPODS
o ATTACH TO VESSEL AND OTHER PLATELETS
o CONTRACT AND PULL WALLS TOGETHER
o DEGRANULATION
PLATELET PLUG FORMATION
* DEGRANULATION
o RELEASE OF COMPOUNDS TO
+ VASOCONSTRICT
+ ATTRACT PLATELETS
+ STIMULATE DEGRANULATION
+ PROMOTE AGGREGATION
o POSITIVE FEEDBACK
CONTROL OF BLEEDING
* COAGULATION (CLOTTING)
* MOST EFFECTIVE DEFENSE
* FIBRINOGEN  FIBRIN  POLYMER
* TWO REACTION PATHWAYS
o EXTRINSIC MECHANISM
+ CLOTTING FACTORS FROM DAMAGED BLOOD VESSEL
o INTRINSIC MECHANISM
+ CLOTTING FACTORS FROM BLOOD
CLOTTING FACTORS
* PROCOAGULANTS
* PROTEINS PRODUCED IN LIVER
* INACTIVE  ACTIVE
o EACH ACTIVATES THE NEXT
o REACTION CASCADE
o AMPLIFICATION AT EACH STEP
o POSITIVE FEEDBACK INVOLVED
* CLOT RETRACTION
o CLOT FORMED
o PLATELETS ADHERE TO FIBRIN
o PLATELETS CONTRACT
o PULLS EDGES OF BROKEN VESSEL TOGETHER
* PLATELETS SECRETE PDGF
o PLATELET-DERIVED GROWTH FACTOR
o STIMULATES MITOSIS
* FIBROBLASTS INVADE AND PRODUCE CONNECTIVE TISSUE

CLOT DISSOLUTION
* FIBRINOLYSIS
* MULTIPLE STEPS
* POSITIVE FEEDBACK
* SIMILAR, IN REVERSE
PREVENTION OF COAGULATION
* PLATELET REPULSION
* DILUTION AND BLOOD MOVEMENT
* ANTICOAGULANTS
o ANTITHROMBIN (LIVER)
o HEPARIN (BASOPHILS)

COAGULATION DISORDERS
HEMOPHILIA

* DEFICIENCY IN A CLOTTING FACTOR
* CASCADE DISRUPTED
* CLOTTING DEFICIENCY
COAGULATION DISORDERS
HEMOPHILIA A
COAGULATION DISORDERS
HEMOPHILIA B
BLOOD CELL PRODUCTION
STEM CELLS
* PLURIPOTENT CELLS
o UNDIFFERENTIATED CELLS
o ABLE TO DIVIDE AND DIFFERENTIATE INTO MULTIPLE TYPES OF CELLS
o NOT ALL ARE “TOTIPOTENT”
o (NOT FULLY DIFFERENTIATED)
o E.G., HEMOCYTOBLASTS (BLOOD)
o E.G., EMBRYONIC STEM CELLS
* YOLK SAC
o EARLIEST HEMOPOIETIC TISSUE
o PRODUCES STEM CELLS
o COLONIZE OTHER ORGANS
+ BONE, LIVER, SPLEEN, THYMUS, ETC
o LIVER STOPS HEMOPOIESIS AT BIRTH
o SPLEEN STOPS ERYTHROPOIESIS SHORTLY AFTER BIRTH
* MYELOID HEMOPOIESIS
o OCCURS IN BONE MARROW
o FORMS ALL SEVEN FORMED ELEMENTS
* LYMPHOID HEMOPOIESIS
o OCCURS IN SEVERAL ORGANS
+ THYMUS, TONSILS, LYMPH NODES, SPLEEN, INTESTINES, ETC.
o PRODUCES LYMPHOCYTES
HEMOCYTOBLASTS
* STEM CELLS
* PLURIPOTENT
* DIFFERENTIATE INTO ALL FORMED ELEMENTS
o ERYTHROPOIESIS
o LEUKOPOIESIS
o THROMBOPOIESIS

ERYTHROCYTE PRODUCTION
ERYTHROPOIESIS
ERYTHROCYTE PRODUCTION
ERYTHROPOIESIS
ERYTHROCYTE HOMEOSTASIS
IRON METABOLISM
ERYTHROCYTE DEATH
HEMOLYSIS
* IRON
* PORPHYRIN RING
LEUKOCYTE PRODUCTION
LEUKOPOIESIS
PLATELET PRODUCTION
THROMBOPOIESIS
PLATELET PRODUCTION

Blood.ppt

Read more...

04 August 2009

Acute Intermittent Porphyria



Acute Intermittent Porphyria
Heme/Onc Grand Rounds
By:Jane Chawla, M.D.

History of Present Illness
Physical Exam & Laboratory Data

* VS: T 36.2 P 142 R 20 BP 178/112
* Gen: Sleepy but arousable, AxO x3
* HEENT: PERRL, EOMI, OP Clear
* Neck: Supple, no LAD
* CV: tachy, regular rhythm, no m/g/r
* Lungs: CTAB
* GI: soft, ND, mild periumbilical discomfort to palpation
* Extr: no c/c/e
* Skin: No rashes or skin lesion
* Neuro: CN II-XII intact, strength 4/5 throughout, paresthesia in bilat lower extremities, 2+ reflexes, upgoing toes



Labs:
Random Problem List?
* Hyponatremia
* Tachycardia
* Hypertension
* Elevated Creatinine
* Abdominal Pain
* Transaminitis
* Weakness
* Cortisol – wnl
Cosyntropin Stim Test – wnl
Urine lytes → SIADH
* EKG – sinus tachycardia
CT Angio (-)
Urine VMA/metanephrine (-)
* Renal Ultrasound – wnl
responded to fluids
* LFTs – Mild transaminitis
CT Abdomen/Pelvis (-)
Hepatitis panel (-)

PORPHYRIA
Heme central to understanding Porphria
* Heme is part of hemoglobin, myoglobin, catalases, peroxidases, and cytochromes
* Heme is made in every human cell (85% in erythroid cells & much of the rest in the liver)
* First enzyme in heme synthesis pathway is ALA synthetase (ALAS)
* Increase demand induces ALAS
* Heme downregulates ALAS by feedback inhibition
* Partial block in this pathway induces ALAS and causes accumulation of heme precursors upstream from block

Porphyria is a disruption in the heme pathway
* Group of metabolic diseases resulting from a partial deficiency of an enzyme in the heme biosynthetic pathway
* Seven enzymes in the pathway
* Four of the porphyrias cause acute attacks
* Increased demand for heme can precipitate attacks secondary to overproduction of toxic heme precursors (porphyrins, ALA)
* The porphyrins have no useful function and act as highly reactive oxidants damaging tissues

Overview of the Seven Porphyrias
Overview of the Four Acute Porphyrias
* Four acute porphyrias cause acute, self-limiting attacks that lead to chronic and progressive deficits
* Symptoms of acute attacks mimic other diseases and increase the potential for misdiagnosis.
* Acute porphyrias are clinically indistinguishable during acute attacks, except the neurocutaneous porphyrias (variegate porphyria and hereditary coproporphyria) can cause dermatologic changes
* Acute attacks lead to an increase in porphobilinogen (PBG) and 5-aminolevulinic acid (ALA) which can be detected in the urine
* Things that make diagnosis difficult: variable clinic course, lack of understanding about diagnostic process, and lack of a universal standard for test result interpretation

Patient Focus: Acute Intermittent Porphyria
* Most common porphyria
* Deficiency of hepatic PBG deaminase
* Autosomal dominant pattern with incomplete penetrance
* Affected individuals have a 50% reduction in erythrocyte PBG deaminase activity
* Latent prior to puberty
* Symptoms more common in females than males
* Increased urinary ALA & PBG

Prevalence in the General Population
Key Clinical Features
* Gastrointestinal symptoms - Abdominal pain (most common presenting complaint), nausea/vomiting, constipation, and diarrhea.
* Dehydration
* Hyponatremia
* Cardiovascular symptoms - tachycardia, hypertension, arrhythmias
* Neurologic manifestations - motor neuropathy, sensory neuropathy, mental symptoms, seizures.

Pathophysiology of the Acute Attack
Autonomic Nervous System
Peripheral Nervous System
Hypothalamus
Limbic area

Porphyrins excreted from liver
ALA crosses BBB
Causes oxidative damage
Accumulates in brain with neuronal and glial cell damage
Symptoms due to porphyrin
Precursor accumulation
Rather than deficiency of Heme
Porphyrins don’t Cross BBB
ALA induces liver
Damage via oxidative effects
Exacerbating Factors of Acute Attack
* Drugs that increase demand for hepatic heme (especially cytochrome P450 enzymes)
* Crash diets (decrease carbohydrate intake)
* Endogenous hormones (progesterone)
* Cigarette smoking (induces cytochrome P450)
* Metabolic stresses (infections, surgery, psychological stress)

Diagnosis of Acute Porphyria
Algorithm for Acute Porphyria Diagnosis
Treatment of the Acute Attack
* Hospitalization to control/treat acute symptoms:
o Seizures – Seizure precautions, medications?
o Electrolyte abnormalities
o Dehydration / hyponatremia
o Abdominal Pain – narcotic analgesics
o Nausea/vomiting – phenothiazines
o Tachycardia/hypertension – Beta blockers
o Urinary retention / ileus
* Withdraw all unsafe medications
* Monitor respiratory function, muscle strength, neurological status
* Mild attacks (no paresis or hyponatremia) – Intravenous 10% glucose at least 300 g per day
* Severe attacks – Intravenous hemin (3-4 mg/kg qdaily for 4 days) ASAP (can give IV glucose while waiting for IV hemin)
* Cimetidine for treatment of crisis and prevention of attacks

Hematin (Panhematin)
* Used in the treatment of the acute porphyrias since the 1970s
* Mechanism of Action: Reduces production of ALA / porphyrins by negative feedback inhibition on ALA synthetase
* Derived from outdated PRBCs from community blood banks
* Reconstitution of lyophilized hematin with 25% albumin recommended
o Reconstituted in sterile water originally –> less stable / degraded easily
o Degradation products cause an ↑ in adverse reactions
* Adverse reactions: Due to degradation products binding to endothelial cells, platelets, & coagulation factors
o Thrombophlebitis
o Anticoagulation (transient ↑ PT, bleeding may occur)
o Thrombocytopenia

* thrombophlebitis if given through large vein or central line
* Dosing:
o Acute attacks: 3-4 mg/kg/day x 4 or more days
o Max daily dose 6 mg/kg or 313 mg (1 vial) – even in obese patients
o Prevention of attacks: not well established; once or twice weekly infusions

A Study of Hemin Use in Clinical Practice

* Hemin approved under Orphan Drug Act of 1983
* Hemin removed from market in 2000 by FDA: 8/00-6/01
o Abbott Laboratories required to conduct open-label study of the safety of hemin manufactured at a new facility
o Largest trial / case series to date on hemin therapy
* Study design: “Real world” data about acute porphyria diagnosis, treatment & perceived efficacy of treatment
* Methods:
o Hemin only available through study participation – compassionate basis
o All pts judged to need hemin by their physicians were enrolled
o Confirmation of diagnosis not required
o Pts received hemin as normally prescribed by their physicians
o No specific outcome measures, exclusion criteria, or follow-up

Results of Hemin Used in Clinical Practice

* Study Population: 130 pts; 92% Caucasian; 72% female
* Precipitating factors: (40/130 pts): drugs (22%); hormonal (24%)
* Results:
o 111 pts treated for 305 acute attacks & 40 pts for prophylaxis
o Diagnostic lab findings reported in 53% (half with +results)
o Hemin regarded as effective for 73% of patients
+ Despite doses less than recommended in 20% of pts (< 3-4 mg/kg/day)
o Propylaxis with hemin in 1/3 of patients
+ Wide variability in prophylaxis regimens  lack of published guidelines
+ Among 31 receiving hemin prophylaxis for >1 month, 68% did not require subsequent tx for acute attacks
o 44% of pts experienced adverse events – most attributed to underlying disease and not hemin
+ Phlebitis was most common adverse event attributed to hematin

Long-Term Complications from Symptomatic Disease

* Neurological Sequelae
* Hypertension
* Renal failure
* Cirrhosis
* Hepatocellular carcinoma

Renal failure: Is hypertension the cause or the effect

* Debate about cause: Hypertension or another etiology?
* Increased risk of renal failure in those with more acute attacks
* Andersson et al  Population-based study (Sweden)
o Renal biopsies (n=16)  ischemic lesions, ? related to protracted vasospasm
o Theory of injury  Vasospasm from:
+ Porphyrin metabolites &
+ an upregulated SNS  ↑ urinary excretion of catecholamines during an acute attack
o By this theory, hypertension is not the sole cause of renal insufficiency

Hepatocellular Carcinoma (HCC)

* Estimated 60 to 70-fold ↑ risk of HCC in AIP patients
* Andersson  Retrospective population-based mortality study
o HCC  27% with AIP vs 0.2% deceased without AIP
o HCC more common in women (2:1)
o HCC more common in those with symptomatic disease
o Cirrhosis more common in AIP pts (12%) vs non-AIP (0.5%)
o Cirrhosis in AIP pts higher in W>M 3:1
* Retrospective analysis for genetic mutations in 17 pts with AIP & HCC (L Bjersing)
o Is PBGD a tumor suppressor gene? (No, 1 allele present in tumor)
o No mutations seen in p53 or ras (these mutations have been implicated in HCC caused by HBV or aflatoxin)
* De Siervi et al ALA is toxic to two hepatocellular cancer cell lines (HEP G2 & HEP 3B)
o Degree of cytotoxicity was directly related to concentration of ALA
o Adding hemin or D-glucose to ALA + cells decreased toxicity with HEP G2 cells
* Proposed Mechanism of cirrhosis / carcinogenesis:
o Reduced free heme pool  ↓ cytochrome P450 & antioxidant enzymes reactive oxygen species DNA damage
o ALA that accumulates can oxidize proteins & cause DNA damage

Prevention & Follow-up: Caring for Patients Between Attacks
* Avoidance of alcohol, smoking, and exacerbating drugs
* Adequate carbohydrate intake
* Medical alert bracelets/wallet cards
* Gonadotropin-releasing hormone analogues
* Iron overload from hemin (100 mg of hemin contains 8 mg of iron)
* Hepatocellular carcinoma screening
* End-Stage renal disease prevention
* Screening for Osteoporosis
o risk from GNRH analogues, immobility, malnutrition, & vitamin D deficiency

Prognosis
* Prior to 1970, fatality rates were 10% to 52%, now 10%
* Since introduction of hematin mortality has decreased
* Overall mortality in patients with acute attacks is 3-fold higher than the general population
* Delayed diagnosis and treatment contribute to higher mortality
Future Treatment Directions
* Liver transplantation
* Animal models used to mimic porphyrias with experiments to correct enzyme deficiency in tissues
* Non-viral mediated gene transfers
If You Were Asleep….Key Points to Remember
* Porphyrias are metabolic diseases resulting from a partial deficiency of an enzyme in the heme biosynthetic pathway
* Cause acute attacks secondary accumulation of heme precursors
* Clinical features: abdominal pain, tachycardia, hypertension, hyponatremia, seizures, motor neuropathy etc.
* Screen for porphyria with qualitative urinary PBG and if elevated measure quantitative urinary PBG and ALA
* Confirm diagnosis with urinary and fecal fractionated porphyrins and DNA testing
* Treat acute attacks with IV hemin
* Prevent acute attacks with smoking cessation, avoidance of inciting agents

References
Acute Intermittent Porphyria.ppt

Read more...

27 May 2009

Systematic Approach in Anemia Evaluation



Systematic Approach in Anemia Evaluation and Review of Peripheral Smears
By:Jun W. Kim, MD
Family Medicine Residency
Dewitt Army Community Hospital

Objective
* Recognize abnormal peripheral blood smear
* Review differentials through systematic approach

Approach to Dx
Basic Labs to Start
Reticulocyte count
Reticulocyte Correction
Reticulocyte Production Index
- Hemolytic disease
- Hemoglobinopathy (including thalassemia)
Peripheral smear
* Optimal area for review
* RBC morphology, WBC differential, PLT (clumping?)
RBC morphology
Basophilic stippling
Burr cells
Elliptocytes/ovalocytes
Howell Jolly body
Schistocyte/helmet cells
Sickle cells
NRBC
Spherocyte
Stomatocyte
Target cells
Tear drop cells
Differentials
MCV/smear
Micro
Normo
Macro
Iron panel
Retic
Iron/B12/Folate
*Occult Blood Loss
Bone Marrow Bx
Anemia of Chronic Dis.
Anemia Differential Dx by Flow Chart
First use size (MCV) to sort the Differential Dx
Microcytic anemia
Iron def. Anemia
Thalassemia
Alpha-thalassemia
Beta-thalassemia
Sideroblastic anemia
Sample questions
Macrocytic anemia
Megaloblastic Anemia
B12
Folate
Aplastic Anemia
Occult Blood Loss?
Hemolytic Anemia
Other Lab Characteristics
* RBC morphology
* Serum haptoglobin
* Serum LDH
* Unconjugated bilirubin
* Hemoglobinuria
* Hemosiderinuria

Coombs’ positive with Spherocytes Autoimmune hemolytic anemia
Warm AIHA
Cold AIHA
Coombs’ positive with Spherocytes Other immune hemolytic anemia
Alloantibody hemolytic anemia
* Transfusion reaction
* Feto-maternal incompatibility (Kleihauer-Betke test)

Drug related Hemolytic anemia
* Toxic immune complex (drug+Ab+C3)
- Quinine, Quinidine, Rifampin, INH, Sulfonamides,
* Hapten formation (anti-IgG)
- PCN, methicillin, ampicillin

Coombs’ Negative Hemolytic anemia
Membrane Defects
Spherocytosis
Elliptocytosis
Coombs’ Negative Hemolytic Anemia Deficiency of RBC Enzymes
Pyruvate Kinase Def.
Coombs’ Negative Hemolytic Anemia Hemoglobinopathy
HbS disease
HbC disease
HbSC disease
Coombs’ Negative Hemolytic Anemia Paroxysmal Nocturnal Hemoglobinuria
Coombs’ Negative Hemolytic Anemia Fragmented RBC’s & Thrombocytopenia
Normocytic Anemia

Anemia Evaluation.ppt

Read more...

17 May 2009

Venous thromboembolism Presentations



Venous thromboembolism
Definition: Thrombosis is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system

Thrombosis and Antithrombotic Therapy

Venous thromboembolism

Venous Thromboembolism: Deep Venous Thrombosis and Pulmonary Embolism
Presentation by:CDR Kenneth S. Yew MC, USN, Uniformed Services University
Edited by Paul Saleeb

Venous Thromboembolic Disease
Presentation by:R. Duncan Hite, MD

Anticoagulant, Antithrombotic and Anti-Platelet Drugs
Presentation by:Robert Taylor, MD, Ph.D.

Thrombophilias
Presentation by:Sharon Sams

Cancer and VTE
Presentation by:Aruna Kommareddy, M.D., Fellow, Hematology and Oncology
Washington University School of Medicine

Anticoagulation in Older Adults
Presentation by:Seki Balogun MD

Thrombosis

Role of laboratory testing for venous thromboembolism
Presentation by:Charles Eby M.D
http://hematology.wustl.edu/conferences/presentations/eby072304.ppt

DVT Prophylaxis of the Medical Patient
Presentation by:Nicole Artz, MD, David Lovinger, MD

Peripheral Vascular Disease
http://nah.southtexascollege.edu/ADN/assets/docs/maila/Peripheral%20Vascular%20Disease%201.ppt

HEMOSTASIS / THROMBOSIS

Read more...

04 May 2009

Blood - Overview, Composition



Blood
Presentation lecture by:Melody Holmes, MT,
Collin County Community College District

Overview of Blood Circulation

Composition of Blood

* Tissue type
* Composition
* Formed elements
o Erythrocytes
o Leukocytes
o Platelets
* Hematocrit

Components of Whole Blood
Physical Characteristics and Volume
* Characteristics
* Color
* pH
* Temperature
* Percentage of body weight
* Average volume

Functions of Blood
* Distribution
* Regulation
* Protection

Distribution
* Transportation
o Gases
o Nutrients
o Metabolic wastes
o Hormones
* System Maintenance
o Body temperature
o pH
o Fluid volume

Protection
* Blood loss
o Plasma proteins and platelets
o Clot formation
* Infection
o Antibodies
o Complement proteins
o WBCs

Blood Plasma
* Solutes
o Proteins
+ Albumin, globulins, clotting proteins
o Lactic acid, urea, creatinine
o Organic nutrients
+ Glucose, carbohydrates, amino acids
o Electrolytes
+ Sodium, potassium, calcium, chloride, bicarbonate
o Respiratory gases
+ Oxygen and carbon dioxide
Formed Elements

* Erythrocytes, leukocytes, and platelets
o WBCs
o RBCs
* Life span
* Production

Erythrocytes

* Physical characteristics
o Shape
o Nucleation
o Organelles
* Hemaglobin
o Function
* Spectrin
o Function

Erythrocytes Gas Transport
* Structural characteristics
o Surface area
o Hemoglobin
o ATP generation
Erythrocyte Function
* RBCs are dedicated to respiratory gas transport
* Hemaglobin (Hb)
o Affinity for oxygen
o Composition
o Heme group
o Capacity

Structure of Hemoglobin
Hemoglobin (Hb)
* Oxyhemoglobin
* Deoxyhemoglobin
* Carbaminohemoglobin

Production of Erythrocytes
* Hematopoiesis
* Red bone marrow
o Axial skeleton and girdles
o Epiphyses of the humerus and femur
* Hemocytoblasts

Production of Erythrocytes: Erythropoiesis
* Hemocytoblast → Proerythroblast
* Proerythroblasts → Early Erythroblasts
* Developmental pathway
o 1 – ribosome synthesis in early erythroblasts
o 2 – Hb accumulation in late erythroblasts and normoblasts
o 3 – ejection of the nucleus from normoblasts and formation of reticulocytes
* Reticulocytes → Mature Erythrocytes

Erythropoiesis: Regulation and Requirements
* Circulating erythrocyte number
o Too few RBCs
o Too many RBCs
* Erythropoiesis control
o Iron, amino acids, and B vitamins

Erythropoiesis: Hormonal Control
* Erythropoietin (EPO)
o Triggers
+ Hypoxia
+ Decreased oxygen availability
+ Tissue demand for oxygen
* Enhanced erythropoiesis
o Outcome
+ RBC count
+ Oxygen carrying ability
Homeostasis: Normal blood oxygen levels
Erythropoietin Mechanism
Homeostasis: Normal blood oxygen levels
Erythropoiesis: Dietary Requirements
Erythrocytes: Fate and Destruction
* Life span
* Degenerate
* Dying RBCs
o Macrophages
* Heme and globin
* Iron
Erythrocytes: Fate and Destruction
* Heme → Bilirubin
* Bilirubin → Bile
* Bile → Urobilinogen
* Stercobilin
* Globin
* Hb
Erythrocyte Disorders
Anemia: Insufficient Erythrocytes
* Hemorrhagic anemia
* Hemolytic anemia
* Aplastic anemia
* Iron-deficiency anemia
o Secondary result
o Iron-containing foods
o Iron absorption
* Pernicious anemia
o Vitamin B12
o Intrinsic factor
* Treatment
o B12
o Nascobal
Anemia: Decreased Hemoglobin Content
Anemia: Abnormal Hemoglobin
* Sickle-cell anemia
o HbS
+ Amino acid substitution
o Result

Polycythemia

* Polycythemia
* Three main polycythemias
o Polycythemia vera
o Secondary polycythemia
o Blood doping

Blood.ppt

Read more...

Blood - Anatomy & Physiology



Blood - Anatomy & Physiology
Presentation lecture by:Elaine N. Marieb
PowerPoint® Lecture Slides prepared by Vince Austin, University of Kentucky
Elaine N. Marieb
Copyright © 2005 Pearson Education, Inc., publishing as Benjamin Cummings


Blood
Overview of Blood Circulation

* Blood leaves the heart via arteries that branch repeatedly until they become capillaries
* Oxygen (O2) and nutrients diffuse across capillary walls and enter tissues
* Carbon dioxide (CO2) and wastes move from tissues into the blood
* Oxygen-deficient blood leaves the capillaries and flows in veins to the heart
* This blood flows to the lungs where it releases CO2 and picks up O2
* The oxygen-rich blood returns to the heart

Composition of Blood

* Blood is the body’s only fluid tissue
* It is composed of liquid plasma and formed elements
* Formed elements include:
o Erythrocytes, or red blood cells (RBCs)
o Leukocytes, or white blood cells (WBCs)
o Platelets
* Hematocrit – the percentage of RBCs out of the total blood volume

Components of Whole Blood
Physical Characteristics and Volume

* Blood is a sticky, opaque fluid with a metallic taste
* Color varies from scarlet (oxygen-rich) to dark red (oxygen-poor)
* The pH of blood is 7.35–7.45
* Temperature is 38C, slightly higher than “normal” body temperature
* Blood accounts for approximately 8% of body weight
* Average volume of blood is 5–6 L for males, and 4–5 L for females

Functions of Blood

* Blood performs a number of functions dealing with:
o Substance distribution
o Regulation of blood levels of particular substances
o Body protection
Distribution

* Blood transports:
o Oxygen from the lungs and nutrients from the digestive tract
o Metabolic wastes from cells to the lungs and kidneys for elimination
o Hormones from endocrine glands to target organs

Regulation

* Blood maintains:
o Appropriate body temperature by absorbing and distributing heat
o Normal pH in body tissues using buffer systems
o Adequate fluid volume in the circulatory system

Protection

* Blood prevents blood loss by:
o Activating plasma proteins and platelets
o Initiating clot formation when a vessel is broken
* Blood prevents infection by:
o Synthesizing and utilizing antibodies
o Activating complement proteins
o Activating WBCs to defend the body against foreign invaders

Blood Plasma

* Blood plasma contains over 100 solutes, including:
o Proteins – albumin, globulins, clotting proteins, and others
o Nonprotein nitrogenous substances – lactic acid, urea, creatinine
o Organic nutrients – glucose, carbohydrates, amino acids
o Electrolytes – sodium, potassium, calcium, chloride, bicarbonate
o Respiratory gases – oxygen and carbon dioxide

Formed Elements

* Erythrocytes, leukocytes, and platelets make up the formed elements
o Only WBCs are complete cells
o RBCs have no nuclei or organelles, and platelets are just cell fragments
* Most formed elements survive in the bloodstream for only a few days
* Most blood cells do not divide but are renewed by cells in bone marrow

Erythrocytes (RBCs)

* Biconcave discs, anucleate, essentially no organelles
* Filled with hemoglobin (Hb), a protein that functions in gas transport
* Contain the plasma membrane protein spectrin and other proteins that:
o Give erythrocytes their flexibility
o Allow them to change shape as necessary

* Erythrocytes are an example of the complementarity of structure and function
* Structural characteristics contribute to its gas transport function
o Biconcave shape that has a huge surface area relative to volume
o Discounting water content, erythrocytes are more than 97% hemoglobin
o ATP is generated anaerobically, so the erythrocytes do not consume the oxygen they transport

Erythrocyte Function

* Erythrocytes are dedicated to respiratory gas transport
* Hemoglobin reversibly binds with oxygen and most oxygen in the blood is bound to hemoglobin
* Hemoglobin is composed of the protein globin, made up of two alpha and two beta chains, each bound to a heme group
* Each heme group bears an atom of iron, which can bind to one oxygen molecule
* Each hemoglobin molecule can transport four molecules of oxygen

Structure of Hemoglobin
Hemoglobin

* Oxyhemoglobin – hemoglobin bound to oxygen
o Oxygen loading takes place in the lungs
* Deoxyhemoglobin – hemoglobin after oxygen diffuses into tissues (reduced Hb)
* Carbaminohemoglobin – hemoglobin bound to carbon dioxide
o Carbon dioxide loading takes place in the tissues

Production of Erythrocytes

* Hematopoiesis – blood cell formation
* Hematopoiesis occurs in the red bone marrow of the:
o Axial skeleton and girdles
o Epiphyses of the humerus and femur
* Hemocytoblasts give rise to all formed elements

Production of Erythrocytes: Erythropoiesis

* A hemocytoblast is transformed into a committed cell called the proerythroblast
* Proerythroblasts develop into early erythroblasts
* The developmental pathway consists of three phases
o Phase 1 – ribosome synthesis in early erythroblasts
o Phase 2 – hemoglobin accumulation in late erythroblasts and normoblasts
o Phase 3 – ejection of the nucleus from normoblasts and formation of reticulocytes
* Reticulocytes then become mature erythrocytes
Production of Erythrocytes: Erythropoiesis

* Circulating erythrocytes – the number remains constant and reflects a balance between RBC production and destruction
o Too few red blood cells leads to tissue hypoxia
o Too many red blood cells causes undesirable blood viscosity
* Erythropoiesis is hormonally controlled and depends on adequate supplies of iron, amino acids, and B vitamins



Regulation and Requirements for Erythropoiesis
Hormonal Control of Erythropoiesis

* Erythropoietin (EPO) release by the kidneys is triggered by:
o Hypoxia due to decreased RBCs
o Decreased oxygen availability
o Increased tissue demand for oxygen
* Enhanced erythropoiesis increases the:
o RBC count in circulating blood
o Oxygen carrying ability of the blood
Erythropoietin Mechanism
Dietary Requirements of Erythropoiesis
Fate and Destruction of Erythrocytes

* The life span of an erythrocyte is 100–120 days
* Old erythrocytes become rigid and fragile, and their hemoglobin begins to degenerate
* Dying erythrocytes are engulfed by macrophages
* Heme and globin are separated and the iron is salvaged for reuse
* Heme is degraded to a yellow pigment called bilirubin
* The liver secretes bilirubin into the intestines as bile
* The intestines metabolize it into urobilinogen
* This degraded pigment leaves the body in feces, in a pigment called stercobilin
* Globin is metabolized into amino acids and is released into the circulation
* Hb released into the blood is captured by haptoglobin and phagocytized

Life Cycle of Red Blood Cells
* Anemia – blood has abnormally low oxygen-carrying capacity
o It is a symptom rather than a disease itself
o Blood oxygen levels cannot support normal metabolism
o Signs/symptoms include fatigue, paleness, shortness of breath, and chills

Erythrocyte Disorders
Anemia: Insufficient Erythrocytes

* Hemorrhagic anemia – result of acute or chronic loss of blood
* Hemolytic anemia – prematurely ruptured erythrocytes
* Aplastic anemia – destruction or inhibition of red bone marrow
* Iron-deficiency anemia results from:
o A secondary result of hemorrhagic anemia
o Inadequate intake of iron-containing foods
o Impaired iron absorption
* Pernicious anemia results from:
o Deficiency of vitamin B12
o Lack of intrinsic factor needed for absorption of B12
* Treatment is intramuscular injection of B12; application of Nascobal
Anemia: Decreased Hemoglobin Content
Anemia: Abnormal Hemoglobin

* Thalassemias – absent or faulty globin chain in hemoglobin
o Erythrocytes are thin, delicate, and deficient in hemoglobin
* Sickle-cell anemia – results from a defective gene coding for an abnormal hemoglobin called hemoglobin S (HbS)
o HbS has a single amino acid substitution in the beta chain
o This defect causes RBCs to become sickle-shaped in low oxygen situations
Polycythemia

* Polycythemia – excess RBCs that increase blood viscosity
* Three main polycythemias are:
o Polycythemia vera
o Secondary polycythemia
o Blood doping

Leukocytes (WBCs)

* Leukocytes, the only blood components that are complete cells:
o Are less numerous than RBCs
o Make up 1% of the total blood volume
o Can leave capillaries via diapedesis
o Move through tissue spaces
* Leukocytosis – WBC count over 11,000 per cubic millimeter
o Normal response to bacterial or viral invasion

Granulocytes

* Granulocytes – neutrophils, eosinophils, and basophils
o Contain cytoplasmic granules that stain specifically (acidic, basic, or both) with Wright’s stain
o Are larger and usually shorter-lived than RBCs
o Have lobed nuclei
o Are all phagocytic cells
* Neutrophils have two types of granules that:
o Take up both acidic and basic dyes
o Give the cytoplasm a lilac color
o Contain peroxidases, hydrolytic enzymes, and defensins (antibiotic-like proteins)
* Neutrophils are our body’s bacteria slayers
Neutrophils
* Eosinophils account for 1–4% of WBCs
o Have red-staining, bilobed nuclei connected via a broad band of nuclear material
o Have red to crimson (acidophilic) large, coarse, lysosome-like granules
o Lead the body’s counterattack against parasitic worms
o Lessen the severity of allergies by phagocytizing immune complexes
* Account for 0.5% of WBCs and:
o Have U- or S-shaped nuclei with two or three conspicuous constrictions
o Are functionally similar to mast cells
o Have large, purplish-black (basophilic) granules that contain histamine
+ Histamine – inflammatory chemical that acts as a vasodilator and attracts other WBCs (antihistamines counter this effect)

Basophils
* Agranulocytes – lymphocytes and monocytes:
o Lack visible cytoplasmic granules
o Are similar structurally, but are functionally distinct and unrelated cell types
o Have spherical (lymphocytes) or kidney-shaped (monocytes) nuclei

Agranulocytes
* Account for 25% or more of WBCs and:
o Have large, dark-purple, circular nuclei with a thin rim of blue cytoplasm
o Are found mostly enmeshed in lymphoid tissue (some circulate in the blood)
* There are two types of lymphocytes: T cells and B cells
o T cells function in the immune response
o B cells give rise to plasma cells, which produce antibodies
Lymphocytes
* Monocytes account for 4–8% of leukocytes
o They are the largest leukocytes
o They have abundant pale-blue cytoplasms
o They have purple-staining, U- or kidney-shaped nuclei
o They leave the circulation, enter tissue, and differentiate into macrophages
Monocytes

* Macrophages:
o Are highly mobile and actively phagocytic
o Activate lymphocytes to mount an immune response
Summary of Formed Elements
* Leukopoiesis is hormonally stimulated by two families of cytokines (hematopoietic factors) – interleukins and colony-stimulating factors (CSFs)
o Interleukins are numbered (e.g., IL-1, IL-2), whereas CSFs are named for the WBCs they stimulate (e.g., granulocyte-CSF stimulates granulocytes)
* Macrophages and T cells are the most important sources of cytokines
* Many hematopoietic hormones are used clinically to stimulate bone marrow

Production of Leukocytes
* All leukocytes originate from hemocytoblasts
* Hemocytoblasts differentiate into myeloid stem cells and lymphoid stem cells
* Myeloid stem cells become myeloblasts or monoblasts
* Lymphoid stem cells become lymphoblasts
* Myeloblasts develop into eosinophils, neutrophils, and basophils
* Monoblasts develop into monocytes
* Lymphoblasts develop into lymphocytes

Formation of Leukocytes
* Leukemia refers to cancerous conditions involving white blood cells
* Leukemias are named according to the abnormal white blood cells involved
o Myelocytic leukemia – involves myeloblasts
o Lymphocytic leukemia – involves lymphocytes
* Acute leukemia involves blast-type cells and primarily affects children
* Chronic leukemia is more prevalent in older people

Leukocytes Disorders: Leukemias

* Immature white blood cells are found in the bloodstream in all leukemias
* Bone marrow becomes totally occupied with cancerous leukocytes
* The white blood cells produced, though numerous, are not functional
* Death is caused by internal hemorrhage and overwhelming infections
* Treatments include irradiation, antileukemic drugs, and bone marrow transplants
Leukemia
* Platelets are fragments of megakaryocytes with a blue-staining outer region and a purple granular center
* Their granules contain serotonin, Ca2+, enzymes, ADP, and platelet-derived growth factor (PDGF)
* Platelets function in the clotting mechanism by forming a temporary plug that helps seal breaks in blood vessels
* Platelets not involved in clotting are kept inactive by NO and prostaglandin I2

Platelets
Genesis of Platelets

* The stem cell for platelets is the hemocytoblast
* The sequential developmental pathway is hemocytoblast, megakaryoblast, promegakaryocyte, megakaryocyte, and platelets
* A series of reactions designed for stoppage of bleeding
* During hemostasis, three phases occur in rapid sequence
o Vascular spasms – immediate vasoconstriction in response to injury
o Platelet plug formation
o Coagulation (blood clotting)
Hemostasis
* Platelets do not stick to each other or to the endothelial lining of blood vessels
* Upon damage to blood vessel endothelium (which exposes collagen) platelets:
o With the help of von Willebrand factor (VWF) adhere to collagen
o Are stimulated by thromboxane A2
o Stick to exposed collagen fibers and form a platelet plug
o Release serotonin and ADP, which attract still more platelets
* The platelet plug is limited to the immediate area of injury by PGI2

Platelet Plug Formation
* A set of reactions in which blood is transformed from a liquid to a gel
* Coagulation follows intrinsic and extrinsic pathways
* The final three steps of this series of reactions are:
o Prothrombin activator is formed
o Prothrombin is converted into thrombin
o Thrombin catalyzes the joining of fibrinogen into a fibrin mesh
Coagulation
Detailed Events of Coagulation

* May be initiated by either the intrinsic or extrinsic pathway
o Triggered by tissue-damaging events
o Involves a series of procoagulants
o Each pathway cascades toward factor X
* Once factor X has been activated, it complexes with calcium ions, PF3, and factor V to form prothrombin activator

Coagulation Phase 1: Two Pathways to Prothrombin Activator
* Prothrombin activator catalyzes the transformation of prothrombin to the active enzyme thrombin
Coagulation Phase 2: Pathway to Thrombin

* Thrombin catalyzes the polymerization of fibrinogen into fibrin
* Insoluble fibrin strands form the structural basis of a clot
* Fibrin causes plasma to become a gel-like trap
* Fibrin in the presence of calcium ions activates factor XIII that:
o Cross-links fibrin
o Strengthens and stabilizes the clot
Coagulation Phase 3: Common Pathways to the Fibrin Mesh
* Clot retraction – stabilization of the clot by squeezing serum from the fibrin strands
* Repair
o Platelet-derived growth factor (PDGF) stimulates rebuilding of blood vessel wall
o Fibroblasts form a connective tissue patch
o Stimulated by vascular endothelial growth factor (VEGF), endothelial cells multiply and restore the endothelial lining

Clot Retraction and Repair

* Two homeostatic mechanisms prevent clots from becoming large
o Swift removal of clotting factors
o Inhibition of activated clotting factors

Factors Limiting Clot Growth or Formation
* Fibrin acts as an anticoagulant by binding thrombin and preventing its:
o Positive feedback effects of coagulation
o Ability to speed up the production of prothrombin activator via factor V
o Acceleration of the intrinsic pathway by activating platelets
* Thrombin not absorbed to fibrin is inactivated by antithrombin III
* Heparin, another anticoagulant, also inhibits thrombin activity



Inhibition of Clotting Factors




* Unnecessary clotting is prevented by the structural and molecular characteristics of endothelial cells lining the blood vessels
* Platelet adhesion is prevented by:
o The smooth endothelial lining of blood vessels
o Heparin and PGI2 secreted by endothelial cells
o Vitamin E quinone, a potent anticoagulant

Factors Preventing Undesirable Clotting

* Thrombus – a clot that develops and persists in an unbroken blood vessel
o Thrombi can block circulation, resulting in tissue death
o Coronary thrombosis – thrombus in blood vessel of the heart

Hemostasis Disorders:
Thromboembolytic Conditions

* Embolus – a thrombus freely floating in the blood stream
o Pulmonary emboli can impair the ability of the body to obtain oxygen
o Cerebral emboli can cause strokes

Hemostasis Disorders:
Thromboembolytic Conditions
* Substances used to prevent undesirable clots include:
o Aspirin – an antiprostaglandin that inhibits thromboxane A2
o Heparin – an anticoagulant used clinically for pre- and postoperative cardiac care
o Warfarin – used for those prone to atrial fibrillation

Prevention of Undesirable Clots
* Disseminated Intravascular Coagulation (DIC): widespread clotting in intact blood vessels
* Residual blood cannot clot
* Blockage of blood flow and severe bleeding follows
* Most common as:
o A complication of pregnancy
o A result of septicemia or incompatible blood transfusions

Hemostasis Disorders

* Thrombocytopenia – condition where the number of circulating platelets is deficient
o Patients show petechiae (small purple blotches on the skin) due to spontaneous, widespread hemorrhage
o Caused by suppression or destruction of bone marrow (e.g., malignancy, radiation)
o Platelet counts less than 50,000/mm3 is diagnostic for this condition
o Treated with whole blood transfusions

Hemostasis Disorders: Bleeding Disorders
* Inability to synthesize procoagulants by the liver results in severe bleeding disorders
* Causes can range from vitamin K deficiency to hepatitis and cirrhosis
* Inability to absorb fat can lead to vitamin K deficiencies as it is a fat-soluble substance and is absorbed along with fat
* Liver disease can also prevent the liver from producing bile, which is required for fat and vitamin K absorption

* Hemophilias – hereditary bleeding disorders caused by lack of clotting factors
o Hemophilia A – most common type (83% of all cases) due to a deficiency of factor VIII
o Hemophilia B – results from a deficiency of factor IX
o Hemophilia C – mild type, caused by a deficiency of factor XI

* Symptoms include prolonged bleeding and painful and disabled joints
* Treatment is with blood transfusions and the injection of missing factors
* Whole blood transfusions are used:
o When blood loss is substantial
o In treating thrombocytopenia
* Packed red cells (cells with plasma removed) are used to treat anemia

Blood Transfusions
* RBC membranes have glycoprotein antigens on their external surfaces
* These antigens are:
o Unique to the individual
o Recognized as foreign if transfused into another individual
o Promoters of agglutination and are referred to as agglutinogens
* Presence or absence of these antigens is used to classify blood groups

Human Blood Groups

* Humans have 30 varieties of naturally occurring RBC antigens
* The antigens of the ABO and Rh blood groups cause vigorous transfusion reactions when they are improperly transfused
* Other blood groups (M, N, Dufy, Kell, and Lewis) are mainly used for legalities

* The ABO blood groups consists of:
o Two antigens (A and B) on the surface of the RBCs
o Two antibodies in the plasma (anti-A and anti-B)
* An individual with ABO blood may have various types of antigens and spontaneously preformed antibodies
* Agglutinogens and their corresponding antibodies cannot be mixed without serious hemolytic reactions

ABO Blood Groups

* There are eight different Rh agglutinogens, three of which (C, D, and E) are common
* Presence of the Rh agglutinogens on RBCs is indicated as Rh+
* Anti-Rh antibodies are not spontaneously formed in Rh– individuals
* However, if an Rh– individual receives Rh+ blood, anti-Rh antibodies form
* A second exposure to Rh+ blood will result in a typical transfusion reaction

Rh Blood Groups

* Hemolytic disease of the newborn – Rh+ antibodies of a sensitized Rh– mother cross the placenta and attack and destroy the RBCs of an Rh+ baby
* Rh– mother becomes sensitized when Rh+ blood (from a previous pregnancy of an Rh+ baby or a Rh+ transfusion) causes her body to synthesis Rh+ antibodies
* The drug RhoGAM can prevent the Rh– mother from becoming sensitized
* Treatment of hemolytic disease of the newborn involves pre-birth transfusions and exchange transfusions after birth

Hemolytic Disease of the Newborn
* Transfusion reactions occur when mismatched blood is infused
* Donor’s cells are attacked by the recipient’s plasma agglutinins causing:
o Diminished oxygen-carrying capacity
o Clumped cells that impede blood flow
o Ruptured RBCs that release free hemoglobin into the bloodstream
* Circulating hemoglobin precipitates in the kidneys and causes renal failure

Transfusion Reactions
Blood Typing

* When serum containing anti-A or anti-B agglutinins is added to blood, agglutination will occur between the agglutinin and the corresponding agglutinogens
* Positive reactions indicate agglutination

Plasma Volume Expanders
* Plasma expanders
o Have osmotic properties that directly increase fluid volume
o Are used when plasma is not available
o Examples: purified human serum albumin, plasminate, and dextran
* Isotonic saline can also be used to replace lost blood volume

* Laboratory examination of blood can assess an individual’s state of health
* Microscopic examination:
o Variations in size and shape of RBCs – predictions of anemias
o Type and number of WBCs – diagnostic of various diseases
* Chemical analysis can provide a comprehensive picture of one’s general health status in relation to normal values
Diagnostic Blood Tests

Blood.ppt

Read more...
All links posted here are collected from various websites. No video or powerpoint files are uploaded on this blog. If you are the original author and do not wish to display your content on this blog please Email me anandkumarreddy at gmail dot com I will remove it. The contents of this blog are meant for educational purpose and not for commercial use. If you use any content give due credit to the original author.

This site uses cookies from Google to deliver its services, to personalise ads and to analyse traffic. Information about your use of this site is shared with Google. By using this site, you agree to its use of cookies.

  © Blogger templates Newspaper III by Ourblogtemplates.com 2008

Back to TOP